MyLeukemiaTeam

Yes, there is a protocol involving Rituxan (rituximab) and Brukinsa (zanubrutinib) for CLL, especially in cases with deletion 17p and no TP53 mutations. Brukinsa is a BTK inhibitor effective for high-risk CLL, and Rituxan is a monoclonal antibody targeting CD20 on B cells. This combination may be recommended for aggressive Show Full Answer

Yes, there is a protocol involving Rituxan (rituximab) and Brukinsa (zanubrutinib) for CLL, especially in cases with deletion 17p and no TP53 mutations. Brukinsa is a BTK inhibitor effective for high-risk CLL, and Rituxan is a monoclonal antibody targeting CD20 on B cells. This combination may be recommended for aggressive or relapsed CLL. Always consult your doctor for personalized treatment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Oral Therapy vs. Traditional Chemotherapy for CLL/SLL | MyLeukemiaTeam

Chronic Lymphocytic Leukemia Treatment Options | MyLeukemiaTeam